EVALUATION OF USE, EFFECTIVENESS AND SAFETY OF ISAVUCONAZOL

Isavuconazole is an authorised antifungal for the treatment of invasive fungal infection (IFI) by Aspergillus in adult patients in which amphotericin B is not appropriate.

AIM AND OBJECTIVES

To assess the conditions of use, effectiveness of isavuconazole (ISA) versus voriconazole (VORI) compared to the SECURE pivotal study in a third level hospital and describe adverse events in ISA group.

MATERIAL AND METHODS

DEMOGRAPHIC DATA

- Sex
- Age
- Type of infection
- Causative fungus
- Duration of treatment
- Immunosuppressive treatment

EFFECTIVENESS

Clinical response (CR):
- Resolution of symptoms
- No need for subsequent antifungals

ADVERSE EVENTS (AEs)

Worsening of underlying symptoms with ISA
Data compilation was carried out through assisted electronic prescription and electronic medical history

STATISTICAL ANALYSIS

R-commander

RESULTS

DEMOGRAPHIC DATA

<table>
<thead>
<tr>
<th>TREATMENT</th>
<th>NUMBER OF PATIENTS</th>
<th>MALE/FEMALE</th>
<th>MEAN AGE</th>
<th>DAYS OF TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISAVUCONAZOL</td>
<td>10</td>
<td>9/1</td>
<td>54,6</td>
<td>49 (14 – 73,5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(46,25-60)</td>
<td></td>
</tr>
<tr>
<td>VORICONAZOL</td>
<td>20</td>
<td>15/5</td>
<td>66,5</td>
<td>15 (11 – 44,5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(58-78,5)</td>
<td></td>
</tr>
</tbody>
</table>

TYPE OF INFECTION

INVASIVE FUNGAL INFECTION (IFI) PROBABLE IFI

TESTS BY CULTURES
- Aspergillus fumigatus (2 vs. 8)
- A. flavus (2 vs. 0)
- A. niger (1 vs. 0)
- A. terreus (0 vs. 2)
- A. sydowii (0 vs. 1)
- Candida lusitaniae (1 vs. 0)
- Lichtheimia (1 vs. 0)

- Positive galactomannan
- CT image

CONCLUSION AND RELEVANCE

Among our population, Isavuconazole was a relatively effective and safe alternative, without relevant differences compared to voriconazole in terms of effectiveness, according to the SECURE pivotal study. A larger sample size would be necessary to verify this data.

REFERENCES

Informe de Posicionamiento Terapéutico de isavuconazol (Cresemba®) en el tratamiento de la aspergilosis invasora y la mucormicosis [Internet]. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/InformesPublicos/docs/IPT-isavuconazol-Cressemba-aspergilosis-mucormicosis.pdf